Home›Research›Compare›Cetrorelix vs PT-141
Peptide ComparisonCetrorelix vs PT-141
Both are Reproductive & Hormonal peptides.
Cetrorelix
Cetrotide
Half-life: ~62 hours
1 providers listed
PT-141
Bremelanotide
Half-life: 2–3 hours
290 providers listed
Cetrorelix carries stronger published evidence (Meta-analysis, 7 key studies) than PT-141 (RCT, 7); both are research compounds.
Cetrorelix
Evidence
Half-life
~62 hours
PT-141
Evidence
Half-life
2–3 hours
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Cetrorelix |
| Less frequent dosing (longer half-life) | Cetrorelix |
| More provider options (1 vs 290) | PT-141 |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Cetrorelix
PT-141
Cetrorelix
GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis.
Optimal GnRH antagonist protocol for ovarian stimulation during ART: systematic review and network meta-analy…
Hydrogel and oleogel formulation of the decapeptide cetrorelix acetate for nasal administration.
Efficacy and safety of different cetrorelix doses in the luteal phase for preventing ovarian hyperstimulation…
+3 more
PT-141
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Bremelanotide: First Approval
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications…
+3 more
About Cetrorelix
Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression
About PT-141
PT-141 is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly within the hypothalamus. Unlike peripherally acting agents, it modulates sexual arousal at the CNS level via dopaminergic pathways, independent of vascular mechanisms. Bremelanotide received FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Cetrorelix
Source: FDA label
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
PT-141
Source: FDA label
FDA prescribing information for bremelanotide identifies transient blood pressure elevation as the primary safety concern. Baseline cardiovascular assessment and BP monitoring are recommended.
PT-141
Oxytocin
Research suggests PT-141 and Oxytocin may produce complementary sexual health effects when combined. PT-141 activates central melanocortin receptors involved in arousal signaling, while oxytocin modulates bonding, reward, and peripheral reproductive pathways.
Antihypertensive medications
Research notes that PT-141 may influence cardiovascular hemodynamics via central melanocortin pathways. Combined use with antihypertensive medications may require monitoring. Consult your prescriber before combining.
Cetrorelix
Not enough vendor pricing yet.
PT-141
Where to source these peptides
Cetrorelix
1 listed
Browse directory →
Providers offeringPT-141
290 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Reproductive & Hormonal Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Cetrorelix vs PT-141 — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/cetrorelix/pt-141